Amarin, a clinical-stage biopharmaceutical company, has promoted chief financial officer (CFO) John Thero to president. He had been CFO since November 2009, a role in which he has been responsible for a significant portion of the company’s operations.
Thero has more than 20 years of senior management experience, including broad responsibilities in finance, business development and commercial operations. Prior to joining Amarin, Thero was CFO at ViaCell, where he helped guide the company to its successful sale, and Abiomed, during its transition from a development-stage company into a commercial entity.
In addition, Frederick Ahlholm, vice president finance, will be principal accounting officer. Ahlholm joined Amarin in March 2010 and has approximately 20 years of financial and management experience at public and private companies. He began his professional career at Ernst & Young and is a certified public accountant (CPA).
A report by broking group Marsh examines the repercussions from the administration of the South Korean company, which filed for bankruptcy protection at the end of August.
Global research by C2FO suggests that smaller businesses are less concerned with the repercussions of Brexit and the upcoming US presidential election.
A squeeze on skilled talent means it now takes an average of seven weeks to fill open permanent roles in finance in the UK according to new research from financial services recruitment firm Robert Half.
Early-stage merger and acquisition deals in Asia-Pacific show nearly 10% year-on-year growth in recent months.